Top 10 Biotechnology Stocks to Watch in Aug 2024: Essential Guide for Investors
What are Biotechnology Stocks?
The biotech sector is a rapidly evolving field that involves the use of biological systems and organisms to develop new products and technologies. This sector encompasses several subfields including pharmaceuticals, agricultural biotechnology, and industrial biotechnology, all of which have significant impacts on human health and the environment. Biotech companies typically focus on developing innovative treatments, improving crop cultivation techniques, and creating sustainable bioengineering solutions.
Key Aspects of Biotech Stocks
Pharmaceutical Biotechnology:
- Companies focused on developing new drugs and treatment methods.
- Examples: Amgen, Biogen and Gilead Sciences.
Agricultural Biotechnology:
- Companies using biotechnology to improve crop cultivation and increase agricultural yields.
- Examples: Monsanto, Syngenta and Corteva.
Industrial Biotechnology:
- Companies developing biotechnological solutions for environmental and production processes.
- Examples: Novozymes, Danisco and BASF.
10 Top Biotechnology Stocks
Novo-Nordisk A/S(NVO.US)
Company overview
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.
Market value of Novo-Nordisk A/S(NVO.US): US$590.258B
Stock price performance in 2024: +28.97%
What's the latest news:
Pfizer Stock Rises: Pfizer's Q2 earnings exceed expectations, raises annual guidance.
Pfizer Stock Rises: Pfizer's Q2 earnings exceed expectations, raises annual guidance.
Novo Nordisk Drug Slows Decline: Novo Nordisk's GLP-1 drug shows promise in slowing cognitive decline in Alzheimer's patients.
Roche to Fast-track Obesity Drugs: Roche plans to expedite the launch of its anti-obesity drugs to compete with rivals.
Fractyl Receives FDA Breakthrough Status: Fractyl's Revita System granted FDA Breakthrough Device Designation for weight loss maintenance.
Vertex Pharmaceuticals(VRTX.US)
Company overview
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Market value of Vertex Pharmaceuticals(VRTX.US): US$130.518B
Stock price performance in 2024: +24.30%
What's the latest news:
Analyst Ratings Update: Several analysts maintained or adjusted their ratings and target prices for Vertex Pharmaceuticals.
Q2 Loss Reported: Vertex Pharmaceuticals reported a loss in Q2 but saw an increase in revenue.
Analyst Assessments: 14 analysts have updated their ratings and target prices for Vertex Pharmaceuticals.
New Drug Application Approved: Vertex Pharmaceuticals' new drug application for suzetrigine has been granted priority review by the FDA.
Full Year Revenue Guidance Raised: Vertex Pharmaceuticals has raised its full-year product revenue guidance.
Regeneron Pharmaceuticals(REGN.US)
Company overview
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Market value of Regeneron Pharmaceuticals(REGN.US): US$120.502B
Stock price performance in 2024: +24.46%
What's the latest news:
Q2 2024 Earnings Preview: Regeneron Pharmaceuticals is set to announce its Q2 2024 earnings on August 1st.
Maintains Buy Rating: Wells Fargo maintains a buy rating for Regeneron Pharmaceuticals with a target price of $1,125.
Price Target Raised: Cantor Fitzgerald raises Regeneron Pharmaceuticals' price target from $1,000 to $1,015.
Q2 Revenue and Profit Growth: Regeneron Pharmaceuticals reports growth in revenue and profit for Q2 2024.
Moderna(MRNA.US)
Company overview
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Market value of Moderna(MRNA.US): US$36.090B
Stock price performance in 2024: -5.31%
What's the latest news:
Stocks Decline: US benchmark indexes closed lower as markets digested corporate earnings and macro data.
Moderna Shares Drop 15%: Moderna's shares fell after the company reduced its sales forecast due to weaker demand for its Covid-19 vaccines.
Economic Data Weakens: US stocks fell as economic data indicated weaknesses in the US economy.
Q2 Earnings Forecast: Analysts predict a loss for Moderna in Q2 with a significant year-over-year revenue decline.
RSV Vaccine Forecast Slashed: Market forecast for RSV vaccines was significantly reduced following CDC's narrowed vaccination recommendations.
Alnylam Pharmaceuticals(ALNY.US)
Company overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Market value of Alnylam Pharmaceuticals(ALNY.US): US$34.484B
Stock price performance in 2024: +40.33%
What's the latest news:
Q2 Earnings Beat: Alnylam Pharmaceuticals posts Q2 EPS of $0.56, beating estimates.
Price Target Raised: Needham maintains buy rating, raises target price to $320.
Executive Stock Sale: Alnylam executive Yvonne Greenstreet sells 15,100 shares.
Insider Selling Noted: Multiple insiders have sold shares over the past year.
Q2 Revenue Report: Alnylam Pharmaceuticals reports Q2 revenue of $659.8M.
argenx SE(ARGX.US)
Company overview
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Market value of argenx SE(ARGX.US): US$30.866B
Stock price performance in 2024: +35.68%
What's the latest news:
Analysts bullish on argenx: Several analysts maintain a buy rating on argenx SE (ARGX), with increased target prices.
Jefferies maintains buy: Jefferies analyst Akash Tewari maintains a buy rating on argenx SE with a target price of $598.
27 experts weigh in: 27 analysts offer diverse ratings for argenx, with recent target price adjustments to $518.41.
Truist maintains buy: Truist Financial analyst Joon Lee maintains a buy rating on argenx SE.
argenx market value surges: Since its IPO, argenx has seen significant market value growth, with sales reaching $875 million in the first half of 2024.
BioNTech(BNTX.US)
Company overview
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Market value of BioNTech(BNTX.US): US$19.443B
Stock price performance in 2024: -23.56%
What's the latest news:
BioNTech Shares Drop: BioNTech underperforms in US-traded European equities, falling 6.4%.
BioNTech Vaccine Progress: BioNTech announces positive clinical trial results for its oncology mRNA vaccine BNT111.
BioNTech Price Target: HC Wainwright & Co. maintains a price target of $113.00 per share for BioNTech.
BioNTech Ownership: Private equity firms and insiders hold 43% and 19% of BioNTech shares, respectively.
Genmab(GMAB.US)
Company overview
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Market value of Genmab(GMAB.US): US$17.993B
Stock price performance in 2024: -10.96%
What's the latest news:
Upgraded to Strong Buy: Genmab's stock was upgraded to a Strong Buy by Zacks due to improved earnings forecasts.
FDA Approval Supports Buy: Genmab received FDA approval, reaffirming the analyst's target price of $50.
Diverse Analyst Ratings: Eight analysts provided diverse ratings for Genmab, with an upward trend in target prices.
Maintains Buy Rating: H.C. Wainwright analyst maintains a Buy rating on Genmab with a target price of $50.
BeiGene(BGNE.US)
Company overview
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Market value of BeiGene(BGNE.US): US$16.972B
Stock price performance in 2024: -10.02%
What's the latest news:
Northbound funds increase: Northbound funds increased their holdings in BeiGene by 1822.88 million yuan, totaling 626.37 million shares.
Index declines: The Guangyin Financial Health Dragon Head Index fell by 0.52%, with BeiGene among the top ten weighted stocks.
Restricted shares issued: BeiGene issued 36.35 million restricted shares due to a stock incentive plan.
Southbound funds reduce: Southbound funds reduced their holdings in BeiGene by 54.28 million shares, decreasing their share percentage.
Weekly drop of 2.41%: BeiGene's stock price fell by 2.41% this week, with the biopharmaceutical sector also declining.
Biomarin Pharmaceutical(BMRN.US)
Company overview
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Market value of Biomarin Pharmaceutical(BMRN.US): US$16.068B
Stock price performance in 2024: -12.24%
What's the latest news:
5-Year CAGR at 2.2%: Over the last five years, BioMarin Pharmaceutical's stock has increased by 11%, underperforming the market.
FAQ
How to Buy Biotechnology Stocks?
Step 1: Opening a Brokerage Account
To start trading stocks, the initial step is to acquire a brokerage account. When choosing an online stock brokerage, there are two critical factors to consider: brokerage offerings and a user-friendly platform. Moomoo app would be helpful.
Step 2: Deciding how many shares to buy
To gain initial experience, it's wise to paper trade using a stock market simulator. Alternatively, start with a small investment amount.
Step 3: Buying stocks using the right order type
To master stock buying, it's essential to understand three critical order types: market orders, limit orders, and stop orders.
Step 4: Placing the stock order with your brokerage
Moomoo Technologies Inc. is providing this content for information and educational use only. Read more